AllianceBernstein’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

AllianceBernstein’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,820	Closed	-$129K	–	3208
2019 Q1	$129K	Sell	3,820 -290	-7%	-$9.69K	﹤0.01%	2992
2018 Q4	$120K	Hold	4,110	–	–	﹤0.01%	2977
2018 Q3	$253K	Buy	4,110 +400	+11%	+$27.1K	﹤0.01%	2912
2018 Q2	$274K	Buy	3,710 +390	+12%	+$30.4K	﹤0.01%	2848
2018 Q1	$218K	Hold	3,320	–	–	﹤0.01%	2819
2017 Q4	$279K	Hold	3,320	–	–	﹤0.01%	2738
2017 Q3	$383K	Hold	3,320	–	–	﹤0.01%	2674
2017 Q2	$388K	Buy	3,320 +1,380	+71%	+$171K	﹤0.01%	2704
2017 Q1	$239K	Hold	1,940	–	–	﹤0.01%	2795
2016 Q4	$264K	Hold	1,940	–	–	﹤0.01%	2789
2016 Q3	$386K	Hold	1,940	–	–	﹤0.01%	2622
2016 Q2	$251K	Buy	1,940 +380	+24%	+$42.3K	﹤0.01%	2747
2016 Q1	$146K	Sell	1,560 -400	-20%	-$43.5K	﹤0.01%	2772
2015 Q4	$397K	Buy	1,960 +310	+19%	+$55.5K	﹤0.01%	2529
2015 Q3	$240K	Buy	1,650 +290	+21%	+$53.2K	﹤0.01%	2726
2015 Q2	$289K	Buy	+1,360	New	+$333K	﹤0.01%	2762

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AllianceBernstein's BLCM Position: Q2 2019 in Review

AllianceBernstein sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 3,820 shares — an estimated $129K sold.

AllianceBernstein first reported a position in BLCM in Q2 2015 and held it in 16 quarters. The position peaked at $397K in Q4 2015. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

AllianceBernstein reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
AllianceBernstein sold 3,820 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $129K.
AllianceBernstein first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 16 quarters.
AllianceBernstein's Bellicum Pharmaceuticals, Inc. position peaked at $397K in Q4 2015.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on AllianceBernstein's 13F filing for Q2 2019, filed 14 Aug 2019.